Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.
Goldman Sachs raised the firm’s price target on Arrowhead (ARWR) to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the ...
TipRanks on MSN
Arrowhead price target raised to $52 from $45 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on Arrowhead (ARWR) to $52 from $45 and keeps an Outperform rating on the shares. The ...
The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback